Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MPL | P40238 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.38 |
| ▸ | CD38 | P28907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775075 | 0.86 | TAAR1 (0.50) | MAOBIDO1AKR1B1 | |
| SCHEMBL3583278 | 0.86 | TAAR1 (0.50) | MAOBIDO1AKR1B1 | |
| Hydrochloric Acid SCHEMBL5176434 | 0.84 | TAAR1 (0.48) | MAOBIDO1AKR1B1ALDH1A1POLB | |
| SCHEMBL8340093 | 0.83 | MAOB (0.38) | MAOBIDO1AKR1B1PNMTP2RX7 | |
| SCHEMBL964459 | 0.83 | IDO1 (0.39) | MAOBIDO1AKR1B1MPLPNMT | |
| SCHEMBL43013 | 0.82 | IDO1 (0.61) | MAOBIDO1ALDH1A1POLBTDP1 | |
| SCHEMBL5415312 | 0.81 | GABRA1 (0.46) | IDO1AKR1B1P2RX7CD38 | |
| SCHEMBL20560274 | 0.81 | AKR1B1 (0.42) | MAOBIDO1AKR1B1MPLALDH1A1 | |
| SCHEMBL1607335 | 0.81 | AKR1B1 (0.46) | IDO1AKR1B1MPLP2RX7CD38 | |
| SCHEMBL1607338 | 0.81 | AKR1B1 (0.42) | IDO1AKR1B1MPLP2RX7CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431706-A | Fatigue-resistant polyurethane elastomer and preparation method and application thereof | 万勋科技(深圳)有限公司 | 2025-02-14 | — | — | CN | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| CN-105505128-B | Near-infrared light response self-repairing coating and preparation method thereof | 南京工业大学 | 2018-05-08 | — | — | CN | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| CN-119431706-A | Fatigue-resistant polyurethane elastomer and preparation method and application thereof | 万勋科技(深圳)有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-111295373-B | Compositions and methods for treating brain injury | 阿泽凡药物公司 | 2024-12-10 | — | — | CN | disclosed |
| EP-3626718-B1 | FIVE-MEMBERED-FUSED-SIX-MEMBERED AZA-AROMATIC RING COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | UNIV XIAMEN (CN) | 2024-05-15 | — | — | EP | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| WO-2005097750-A1 | SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005035492-A1 | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | SERENIX PHARMACEUTICALS, LLC. (US) | 2005-04-21 | — | — | WO | disclosed |
| CN-1606554-A | Beta-lactam vasopressin V1a Antagonists | SERENIX PHARMACEUTICALS LLC (US) | 2005-04-13 | — | — | CN | disclosed |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AZEVAN PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| EP-1434763-A2 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | Serenix Pharmaceuticals, LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031407-A2 | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS | SERENIX PHARMACEUTICALS, LLC (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | MAOB 217/4885IDO1 3872/4885AKR1B1 3052/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | MAOB 2886/4885IDO1 1950/4885AKR1B1 505/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | MAOB 247/4885IDO1 2561/4885AKR1B1 1156/4885 |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AVPR1A, AVPR2, AVPR1B | MAOB 3085/4885IDO1 1549/4885AKR1B1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.